跳至主要内容
临床试验/NCT02377934
NCT02377934已完成不适用

Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study

University Medical Center Groningen1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2012年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
9
试验地点
1
主要终点
Changes in pulmonary artery pressure

研究概览

简要总结

In the radiotherapeutic treatment of lung cancer, the dose that can be safely applied to the tumour is limited by the risk of radiation induced lung damage. This damage is characterized by parenchymal damage and vascular damage. In rats, we have found that radiation-induced vascular damage results in increased pulmonary artery pressure. Interestingly, the consequent loss of pulmonary function could be fully explained by this increase in pulmonary artery pressure. We hypothesize that also in patients a radiation induced increase in pulmonary artery pressure can be observed after radiotherapy, which may contribute to the development of radiation pneumonitis.

The objective is to test the hypothesis that radiotherapy for lung cancer induces an increase in pulmonary artery pressure.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • WHO PS 0-2
  • Histological or cytological confirmation of non-small cell lung cancer or an 18F-FDG-positive, growing mass on CT-thorax suggestive of NSCLC.
  • Stage IIIA or IIIB
  • Patients with extensive mediastinal lymph node involvement (such as N3), or large primary tumour size
  • Adequate pulmonary function estimated by flow volume curves
  • Life expectancy of at least 6 months
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol; those conditions should be discussed with the patient before registration in the trial.
  • Planned for 25 x 2.4 Gy, with concomitant chemotherapy
  • Before patient registration, written informed consent will be obtained.

排除标准

  • Presence of contra-indications for undergoing MRI

结局指标

主要结局

Changes in pulmonary artery pressure

时间窗: 6 and 12 weeks after completion chemoradiotherapy

次要结局

  • Pulmonary artery velocity; right ventricle (RV) dimensions and RV-function(6 and 12 weeks after completion chemoradiotherapy)
  • The incidence of radiological signs of pulmonary fibrosis according to CTCAE4.0(12 weeks after completion of treatment)
  • The assessment of RV-dimensions and RV-function(6 and 12 weeks after completion chemoradiotherapy)
  • The incidence of clinical signs of radiation pneumonitis according to SWOG-criteria(6 weeks after completion treatment)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验